Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
41 Leser
Artikel bewerten:
(0)

Global Endocrine Testing Market, 2025 - Market is Expected to Reach US$ 14,758.6 Million

DUBLIN, November 29, 2017 /PRNewswire/ --

The "Global Endocrine Testing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global endocrine testing market was valued at US$ 7,359.4 Mn in 2016, and is expected to reach US$ 14,758.6 Mn by 2025, expanding at a CAGR of 7.9% from 2017 to 2025.

The global endocrine testing market is driven by increasing incidence of hormonal imbalances in individuals across all age groups. Such increase in disease incidence has resulted in development of advanced diagnostic technologies thus increasing the demand for sophisticated testing methods. However, it is anticipated that significant costs involved in development of advanced testing techniques may hold back rapid commercialization of these technologies in the market, thereby restrain the market growth.

Among the various test types used in endocrine diagnostics, insulin testing and thyroid stimulating hormone test will account for the largest market share throughout the forecast period. High incidence of hyper - and hypothyroidism and increasing prevalence of diabetes are the key drivers of these segments. Additionally, being chronic in nature, these diseases demand periodic monitoring through testing methods, and at higher frequencies. This fact will ensure the dominance of these segments during the forecast period.

Geographically, North America currently leads the global endocrine testing market, in terms of revenue generation. High incidence of several types of endocrine diseases, swift adoption of novel testing techniques supported by regulatory infrastructure and positive reimbursement scenario mainly contribute to the dominance of North America on the global front. Asia Pacific is observed to be the fastest progressing regional market for endocrine testing. Changes in lifestyle leading to increasing prevalence of chronic diseases and huge target population base are the prime drivers of Asia Pacific market.

Key Topics Covered:

Chapter 1. Preface

1.1. Report Scope and Description

1.2. Research Methodology

Chapter 2. Executive Summary


2.1. Global Endocrine Testing Market Portraiture


2.1.1. Global Endocrine Testing Market, by Test Type, 2016


2.1.2. Global Endocrine Testing Market, by Endocrine Disorders, 2016


2.1.3. Global Endocrine Testing Market, by Testing Technology, 2016


2.1.4. Global Endocrine Testing Market, by End-user, 2016


2.1.5. Global Endocrine Testing Market, by Geography, 2016

Chapter 3. Endocrine Testing: Market Dynamics and Outlook


3.1. Market Overview


3.2. Drivers


3.3. Challenges


3.4. Opportunities


3.4.1. Attractive Investment Proposition, by Geography


3.5. Competitive Landscape


3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Endocrine Testing Market, by Test Type, 2015 - 2025 (US$ Mn)


4.1. Overview


4.1.1. Attractive Investment Proposition, by Test Type


4.2. Estradiol (E2) Testing


4.3. Follicle Stimulating Hormone (FSH) Testing


4.4. Human Chorionic Gonadotropin (hCG) Hormone Testing


4.5. Luteinizing Hormone (LH) Testing


4.6. Dehydroepiandrosterone Sulfate (DHEAS) Testing


4.7. Progesterone Testing


4.8. Testosterone Testing


4.9. Thyroid Stimulating Hormone (TSH) Testing


4.10. Prolactin Testing


4.11. Cortisol Testing


4.12. Insulin Testing


4.13. Others

Chapter 5. Global Endocrine Testing Market, by Endocrine Disorders, 2015 - 2025 (US$ Mn)


5.1. Overview


5.1.1. Attractive Investment Proposition, by Endocrine Disorders


5.2. Adrenal Disorders


5.3. Calcium Problems


5.4. Glucose (islet cells) Disorders


5.5. Male and Female Gonadal Problems


5.6. Heart Disorders


5.7. Hypertensive Disorders


5.8. Thyroid Disorders


5.9. Pituitary Disorders

Chapter 6. Global Endocrine Testing Market, by Testing Technology, 2015 - 2025 (US$ Mn)


6.1. Overview


6.1.1. Attractive Investment Proposition, by Testing Technology


6.2. Immunoassay Technology


6.3. Tandem Mass Spectrometry


6.4. Sensors Technology


6.5. Monoclonal and Polyclonal Antibody Technology


6.6. Clinical Chemistry Technology


6.7. Others

Chapter 7. Global Endocrine Testing Market, by Testing Technology, 2015 - 2025 (US$ Mn)


7.1. Overview


7.1.1. Attractive Investment Proposition, by Testing Technology


7.2. Hospitals


7.3. Clinical Laboratories


7.4. Research and Academia


7.5. Others

Chapter 8. Global Endocrine Testing Market, by Geography, 2015 - 2025

Chapter 9. Company Profiles




  • Abbott Laboratories, Inc.
  • AB Sciex Pte Ltd.
  • Agilent Technologies, Inc.
  • Biomedical Technologies (Alfa Aesar)
  • bioMrieux SA
  • Bio-Rad Laboratories, Inc.
  • DiaSorin
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings

For more information about this report visit https://www.researchandmarkets.com/research/5gkbmk/global_endocrine

Media Contact:


Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.